

Bacteriological profile and antimicrobial resistance of blood culture isolates

Mitra Barati^{1*}, Mahshid Talebi Taher¹, Roshanak Abasi¹, Mona Mohammad Zadeh¹, Mardjan Barati¹, Ahmad Reza Shamshiri²

¹ Pediatric Infectious Diseases Research Centre, Iran University of Medical Sciences, Tehran, Iran

² Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

Background: Bloodstream infection (BSI) is an important cause of mortality and morbidity and among the most common health-care associated infections. In this study we described the frequency of occurrence and antimicrobial susceptibility patterns of nosocomial and community-acquired BSI isolates from a teaching hospital in Tehran, Iran.

Patients and methods: This cross-sectional study was conducted in 850-bed Rasul Akram university hospital from April 2006 to April 2007. All patients with a positive blood culture were enrolled. Antimicrobial susceptibility testing was performed with disk diffusion and E-test MIC.

Results: During the study period, 456 isolates were obtained from blood cultures, from a total of 8818 collected sets, among which 291 were felt to represent true bacteremia and 98 were nosocomial. *Acinetobacter* spp. were the most frequently isolated agents in the hospital and community acquired BSIs (32%), followed by *Escherichia coli* (13.7%) and *Klebsiella* spp. (12%). The most effective antibiotics for gram-negative and gram-positive bacteria were ciprofloxacin (13% resistance rate) and vancomycin and oxacillin (with 13% resistance rate), respectively. Analysis of antibiotic resistance pattern showed that 20.43% of *Acinetobacter* spp. and 15.4% of *Pseudomonas aeruginosa* were multi drug resistant (MDR), while 48.7% of *Klebsiella* spp were ESBL-producing isolates and 15% of *Staphylococcus aureus* were oxacillin-resistant.

Conclusion: We did not observe any vancomycin-resistant strains among isolates of *S. aureus*. Rifampin and ciprofloxacin showed good activity against most of gram-positive and gram-negative organisms, respectively. Carbapenems (imipenem and meropenem) were highly active against strains of Enterobacteriaceae (*E. coli*, *Klebsiella*) that showed resistance to third generation of cephalosporines.

Keywords: Bloodstream infection, Nosocomial infection, Antimicrobial susceptibility pattern..
(*Iranian Journal of Clinical Infectious Diseases* 2009;4(2):87-95).

INTRODUCTION

Bloodstream infection (BSI) is an important cause of mortality and morbidity and among the most common health-care associated infections (1).

Wide spectrums of organisms have been described and this spectrum is subject to geographical alteration.

In a prospective multicenter study of BSI, Weinstein et al. noted substantial changes in the microbiology, epidemiology and clinical and prognostic significance of positive blood cultures over a 20-year period. They found that

Received: 24 September 2008 Accepted: 24 December 2008

Reprint or Correspondence: Mitra Barati, MD.

Pediatric Infectious Diseases Research Centre, Rasul Akram Hospital, Niayesh Avenue, Satarkhan Street, Tehran, Iran.

E-mail: mitra_baraty@yahoo.com

Staphylococcus aureus and *Escherichia coli* continued to be the most common etiologic agents of BSI and noted important increases in BSI due to coagulase-negative staphylococcus, fungi, and *Pseudomonas aeruginosa* (community acquired) (2).

One of the more alarming recent trends in infectious diseases is the increasing frequency of antimicrobial resistance among microbial pathogens causing nosocomial and community-acquired infections. Numerous classes of antimicrobial agents have become less effective as a result of the emergence of antimicrobial resistance, often as result of selective pressure of antimicrobial usage (3).

These resistance trends and the clinical significance and changing spectrum of microbial pathogens argue strongly for antimicrobial resistance surveillance. Such a program will play a critical role in guiding physicians toward appropriate agents for use in the treatment of both community- and hospital-acquired BSI, as well as identifying changing patterns of etiologic agents and drug susceptibility. Most previous studies of BSI have been performed in temperate developed countries (1-9). These studies have mainly focused on nosocomial infections (10-12), especially those acquired in an intensive care unit (13,14).

In the present study we described the frequency of occurrence and antimicrobial susceptibility patterns of nosocomial and community-acquired BSI isolates from a teaching hospital in Tehran.

PATIENTS and METHODS

This cross sectional study was conducted in 850-bed Rasul Akram university hospital from April 2006 to April 2007. All patients with a positive blood culture were enrolled.

All clinical and laboratory data were prospectively collected. The initial data including age, sex, underlying disease, source of infection,

nosocomial and previous antibiotic use were gathered by a prepared questionnaire. Laboratory data including culture and sensitivity results from blood were also recorded. Antimicrobial susceptibility testing was achieved with disk diffusion and E-test MIC. The antimicrobial agents tested were as follows: amikacin; ampicillin; cephalothin, ceftriaxone, ciprofloxacin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin, imipenem, and cefixime. Blood cultures were taken on a routine basis when sepsis was suspected on clinical ground such as fever, tachycardia, tachypnea, or leukocytosis/leucopenia (15).

All blood samples were processed in microbiology laboratory according to the standard procedures (16). Indeed, 5 ml of blood was obtained from each adult patient and inoculated immediately into 50 ml of 'Brain Heart Infusion (BHI)' broth. The broths were subcultured on 5% sheep blood agar and MacConkey agar after overnight incubation. Subcultures were performed on days 1, 2, 3, 5, 7 and 10. Positive growth was identified by gram staining, colony characteristics, and standard biochemical tests.

Disk diffusion testing was performed by standard NCCLS methodology (17), using Muller-Hinton plates supplemented with 5% added sheep blood inoculated with a 0.5 Mcfarland suspension. After overnight incubation in both air and 5% CO₂ at 35°C, zone diameters were measured with calipers.

Standard methodology was used to determine E-test MICs (18). Muller-Hinton plates supplemented with added 5% sheep blood were inoculated with a 0.5 Mcfarland suspension scraped from plates, and E-test strips (AB Biodisk, Solna, Sweden) were placed on each plate. After overnight incubation at 35°C, the MIC was read as the intersect where the ellipse of growth inhibition intersects the strip. E-test MICs were determined both in air and in CO₂. The breakpoints used to define susceptible, resistant and intermediate

categories for each antimicrobial agent were those recommended by the National Committee for Clinical Laboratory Standards (NCCLS). *E.coli* ATCC 25922, *S.aureus* ATCC 29213, *E. faecalis* ATCC 29212, and *P. aeruginosa* ATCC 27853 were used as control.

A blood culture was considered to be contaminated if one or more of the following organisms were identified in only one of a series of blood culture specimens: coagulase-negative *Staphylococcus* species, *Propionibacterium acnes*, *Micrococcus* species, viridians-group streptococci, *Corynebacterium* species, or *Bacillus* species (19). Previous antibiotic use was defined as any antibiotic treatment during 4 weeks preceding hospital admission. Long-term oral corticosteroid use was defined as administration of corticosteroids (≥ 20 mg/day) for ≥ 1 month during the previous 3 months. Considered comorbidities included the presence of diabetes mellitus, malignant neoplasm, renal failure and IV abusing. The bacterial isolates were considered nosocomial isolates if they were cultured more than 48 hours after admission or within 30 days of hospital discharge. Otherwise, the isolates were considered community-acquired. The sources of infections were classified as one of the following: respiratory tract, genitourinary tract, intra-abdominal, unknown (when no obvious source of bacteremia was identified), or others. *Klebsiella* spp. isolates with increased MIC results (≥ 2 $\mu\text{g/ml}$) for ceftazidime and/or ceftriaxone were considered as potential ESBL (extended-spectrum β -lactamas)-producing isolates (9,18). MDR-*P. aeruginosa* and *-Acinetobacter* were defined as resistant to three or all four following antibiotics: ceftazidime, ciprofloxacin, gentamicin, and imipenem (17,20). The study protocol was approved by the Medical Ethics Committee of Iran University of Medical Sciences.

Results are presented as frequency (%) for qualitative or mean \pm standard deviation (SD) for quantitative variables. The association between variables was assessed using the McNemar test.

RESULTS

During the study period, there were 456 (5.17%) episodes in which an isolate was obtained from blood cultures, from a total of 8818 collected sets. Of these, 291(3.3%) were felt to represent true bacteremia, and 98(33.7%) of these were nosocomial and 166 patients (57%) had no underlying disease. Characteristic of 291 patients with true bactremia are presented in table 1.

Table 1. Characteristics of 291 patients with true bacteremia admitted in Rasul Akram hospital

	Number (%)
Sex	
Male	157(54.0)
Female	134(46.0)
Age (years)	
0-18	72(24.0)
19-39	51(17.0)
40-59	42(14.4)
60-79	90(30.9)
≥ 80	36(12.4)
With comorbidity	
Diabetes mellitus	45(15.5)
Corticosteroid use	45(15.5)
Malignant neoplasm	25(8.6)
IV addiction	20(6.9)
Renal failure	19(6.5)
Source of infection	
Unknown	111(38.3)
Respiratory tract	55(18.9)
Genitourinary tract	39(10.7)
Intra-abdominal	24(8.2)
Others	70(24.0)
Ward	
Internal	116(39.9)
ICU	75(25.8)
Emergency	45(15.5)
Pediatric	30(10.3)
Surgery	25(8.6)
Nosocomial infections	98(33.7)
Previous antibiotic use	103(35.4)
Nursing home	8(2.7)

The study population included 157 males and 134 females with the mean age (\pm SD) of 46.0 ± 29.6 years (a range, 1-98 years). Sources of bacteremia included respiratory tract (18.9%), genitourinary tract (10.7%), and intra-abdominal (8.2%) (table 1).

Four bacterial genera were identified in nearly 70% of episodes of bacteremia. These were *Acinetobacter* spp. (32%; 21 *A. baumannii* and 72 *A. lowfii*), *E. coli* (13.7%), *Klebsiella* (12%; 13 *K. pneumoniae* and 22 others), *Pseudomonas aeruginosa* (12%), *Alkaliginosa* (7.2%), *Enterobacter* (6.9%), *Staphylococcus aureus* (6.9%), *Moraxella* (5.5%), *Serratia* (2.7%), *Enterococcus* (1.7%), *Proteus* (0.7%), group-D *Streptococcus* (0.7%), *Viridanse Streptococcus* (0.3%), *Strptococcus pneumoniae* (0.3%), and *Hafnia* (0.3%).

Overall resistances are shown in tables 2 and 3. Among gram-negative isolates, 13% were resistant to ciprofloxacin, nevertheless, ciprofloxacin was superior to all antimicrobial agents ($p < 0.001$). Similarly, among gram-positive isolates, 13.8% were resistant to oxacillin and 13.4% to vancomycin, even though, oxacillin and vancomycin were superior to penicillin G, ceftriaxone, and cefixime ($p < 0.001$, 0.03, and 0.001, respectively), with a trend towards imipenem, gentamicin, and erythromycin superiority that was not statistically significant ($p < 1.00$, 0.50, and 0.25, respectively). All *S. aureus* isolates were sensitive to vancomycin. Rifampin and oxacillin were superior to penicillin G, cefixime, and ceftriaxone ($p < 0.001$, 0.001 and 0.03, respectively), with a trend towards ciprofloxacin, erythromycin, and meropenem that was not statistically significant ($p < 0.12$, 0.25 and 1.00, respectively) for *S. aureus* isolates.

Analysis of antibiotic resistance pattern showed that 20.4% of *Acinetobacter* spp. and 15.4% of *P. aeruginosa* were MDR, while 48.7% of *Klebsiella* spp were ESBL-producing isolates. The rate of ESBL-producing *Klebsiella* spp. was higher among young patients (≤ 18 y) at rate of 80%. Moreover, patients aged 60-79 years were more likely to be infected with an oxacillin-resistant strain of *S. aureus* (50%) than patients in the other age groups (0-33.3%) (table 4).

Table 3. Resistance among gram-positive isolates by E.test

Antimicrobial agent	S.aureus		Enterococcus		Total [#]
	MIC ₅₀ /MIC ₉₀ [†]	%R [‡]	MIC ₅₀ /MIC ₉₀	%R	
B-lactams					
Penicillin G	8/256	95.0	8/256	100	89.7
Oxacillin	0.5/64	15.0	NT	NT	13.8
Cephalothin	3/256	25.0	256/256	100	20.7
Cefixime	12/256	88.9	NT	NT	55.2
Ceftriaxone	8/256	68.8	NT	NT	44.8
Imipenem	0.064/32	21.1	1.5/32	75.0	31.0
Meropenem	0.19/32	33.3	8/32	75.0	24.1
Aminoglycosides					
Gentamicin	0.19/192	31.3	256/256	75.0	31
Others					
Clindamycin	0.094/256	26.3	NT	NT	24.1
Erythromycin	0.125/256	33.6	NT	NT	31.0
Rifampin	0.016/0.38	6.7	4/16	75.0	20.7
Vancomycin	1/1.5	0	2/2	50.0	13.8
Ciprofloxacin	0.19/32	36.8	32/32	75.0	34.5

[†] MIC₅₀ and MIC₉₀, MICs at which 50% and 90% of the isolates, respectively, were inhibited. The units for all MICs are micrograms per milliliter; [‡]%R: percent of isolates resistance per NCCLS criteria (17); [#]Total resistances in all 5 gram-positive isolates. NT: not tested.

Patients in ICUs were at a higher risk for acquiring a BSI caused by MDR-*P.aeruginosa* (31.8%), ESBL-producing *Klebsiella* spp. (77.8%), and oxacillin-resistant *S.aureus* (60%) compared to patients hospitalized in a non-ICU setting, where these pathogens were isolated at rates of 26.8%, 50%, and 0% , respectively (table 4).

Patients who derived their infection from the hospital environment were at a higher risk for sepsis by a pathogen with a resistant phenotype compared to patients with community-acquired infections. MDR-*acinetobacter*, MDR-*P.aeruginosa*, ESBL-producing *Klebsiella* spp., and oxacillin-resistant *S.aureus* were more common among nosocomial isolates (22.2%, 34.5%, 62.5%, and 37.5%, respectively) compared to strains acquired from community infections (11.8%, 14.1%, 52.9%, and 0%, respectively) (table 4). Similar scenario was found for a history of antibiotic and corticosteroid use (table 4).

Oxacillin-resistant *S. aureus* was more common among patients with diabetes mellitus (66.7%) compare to non-diabetics (6.3%) (table 4).

Table 2. Resistance among gram-negative isolates by E. test.

Antimicrobial agent	Acinetobacter		E.coli		Klebsiella		Pseudomonas		Total [#]	
	MIC ₅₀ /MIC ₉₀ [†]	%R [‡]	MIC ₅₀ /MIC ₉₀	%R	MIC ₅₀ /MIC ₉₀	%R	MIC ₅₀ /MIC ₉₀	%R	%R	%R
β- lactams										
Ampicillin	256/256	81.7	256/256	87.5	256/256	94.3	256/256	76.2	77.9	
Cephalothin	256/256	92.5	256/256	60.0	256/256	68.8	256/256	76.9	79.8	
Ceftazidime	6/256	30.1	6/256	20.0	0.5/256	37.1	4/256	26.9	28.6	
Cefixime	256/256	92.5	8/256	53.8	1/256	54.3	256/256	69.2	72.1	
Ceftriaxone	256/256	91.4	96/256	50.0	4/256	51.4	256/256	65.4	69.5	
Imipenem	32/32	73.1	0.19/0.75	2.5	0.25/0.75	5.7	4/32	42.3	35.5	
Meropenem	32/32	62.4	0.047/0.25	5.0	0.047/0.125	5.7	1.5/32	30.8	29.8	
Aminoglycosides										
Amikacin	64/256	50.5	2/16	2.5	4/48	14.3	33/256	46.2	29.8	
Gentamicin	32/256	67.7	64/256	70.0	64/256	57.1	24/256	57.7	61.1	
Others										
Trimethoprim-sulfamethoxazole	0.5/32	18.3	32/32	67.5	2/32	42.9	1.5/32	34.6	34.4	
Ciprofloxacin	2/32	8.6	0.38/32	47.5	0.094/16	17.1	0.25/2	11.5	13.7	

[†] MIC₅₀ and MIC₉₀, MICs at which 50% and 90% of the isolates, respectively, were inhibited. The units for all MICs are micrograms per milliliter; [‡] %R: percent of isolates resistance per NCCLS criteria (17); [#] Total resistances in all 10 gram-negative isolates.

Table 4. Patient risk factor assessment for resistant phenotypes among bloodstream infection pathogens

Organism	Risk factors (% resistant) [†]														
	Age (years)					Intensive care		Source of infection		DM		Prior AB use		Corticosteroid use	
	1-18	19-39	40-59	60-79	>80	Yes	No	NI	Community-acquired	Yes	No	Yes	No	Yes	No
MDR-P. aeruginosa [‡]	15.4	0	0	25.0	0	11.1	17.6	22.2	11.8	0	16.0	28.6	10.5	50.0	9.1
MDR-Acinetobacter spp [‡]	16.7	14.3	23.5	20.0	28.6	31.8	26.8	34.5	14.1	22.2	20.0	30.8	13.0	38.5	17.5
ESBL-phenotype Klebsiella spp [#]	80.0	66.7	40.0	25.0	100	77.8	50.0	62.5	52.9	26.0	64.3	64.3	52.5	85.7	50.0
Oxacillin-resistant S. aureus	0	0	33.3	50.0	0	60.0	0	37.5	0	66.7	6.3	50.0	6.7	66.7	6.3

[†] Resistant criteria according to NCCLS criteria (17).

[‡] Strains were resistant to three or all four following antibiotics: ceftazidime, ciprofloxacin, gentamicin, and imipenem.

[#] Rates were based upon an MIC value of $\geq 2\mu\text{g/ml}$ for ceftazidime or ceftriaxone.

MDR: Multi drug resistant, ESBL: Extended-spectrum β-lactamas, DM: Diabetes mellitus, AB: Antibiotic, NI: Nosocomial infection.

DISCUSSION

In this study, 63% of positive blood cultures were felt to represent true bacteremia, which is near to Douglas et al. (52%) (21) but more than Uslan et al. (38%) (6) and Sucu et al. (46%) (22).

The most commonly isolated group in most of the prior studies was gram-positive organisms (1,6,8), although the range of organisms causing bacteremia differ widely. *S. aureus* was the most common in some (1,3,4,5,7,9,21) and *E.coli* in others (6,8). In our setting, *Acinetobacter* spp. was more frequently isolated. Reports of *Acinetobacter* spp. bacteremia are increasing (8,23) especially from Asian countries, and neighborhood countries of Iran such as Iraq, Kuwait, Turkey and Afghanistan (24-27). Although the trend of these infections has been focused on hospitalized patients, there is another patient population that may be affected by this important pathogen; namely, patients in community setting that have some form of morbidity, especially in the tropical and sub-tropical climates (24,28).

Similarly to others, the most common source of BSI was respiratory tract (18.9%), followed by genitourinary tract (10.7%). Moreover, DM was the most frequently reported underlying disease (8,21).

The percentage of carbapenem-resistant *Acinetobacter* spp. isolates (approximately 70%) was substantially more than other reports, in which this figure ranged 3-30% (7,20,30-33), however, in Ranjbar study it all isolates were resistant to carbapenems (29). Carbapenem resistance among *acinetobacter* isolates appears to be increased, partly because of wide-spread unnecessary use of carbapenem in Iran.

In our study, the resistance rate of *acinetobacter* and *P. aeruginosa* (non-fermenting bacteria) to ciprofloxacin was relatively low (8.6% and 11%, respectively). This in agreement with studies performed in Far East and United Kingdom (32,34, 35). Nevertheless, a much higher rate of

ciprofloxacin resistance was reported from North America and north European countries where resistance ranged from 33 to 92% (7,20,30,31,36) for *acinetobacter*. Furthermore, in America (3,7,20) and India (23) *P. aeruginosa* resistance to ciprofloxacin ranged from 20 to 50%. Resistance of non-fermenting bacteria to fluoroquinolones is a major problem in many parts of the worlds. It appeared that the selection pressure caused by the indiscriminate use of fluoroquinolones was responsible for the persistence and spread of resistant *acinetobacter* (33). This selection pressure is much stronger when the antimicrobial agents are given intravenously than when they are given orally (37). Although oral forms of fluoroquinolones are used frequently in Iran, its only available intravenous agent (ciprofloxacin) is rarely used. Trimethoprim-sulfamethoxazole has the same story in Iran.

Not surprisingly, amikacin was more active than gentamicin in non-fermenting bacteria. Accordingly, in a study from USA, amikacin resistance rate (11.3-15.7%) was significantly lower than gentamicin (44.4-51.9%) (20). Moniri et al reported similar findings, in which *P. aeruginosa* resistance to amikacin (17%) was lower than gentamicin (31%) (38). Superiority of amikacin was also reported by others (3,7,39).

The rate of MDR-*acinetobacter* is increasing in many parts of the world and poses a serious therapeutic dilemma. In some institutes, the treatment of MDR-*acinetobacter* is being limited to polymixin B (24,30). In this study, the rate of MDR-*acinetobacter* isolates was low (20.43%) compared to other study from Iran (100%) (29), but the same as Halstead et al. study (29.3%) (40). MDR-*P.aeruginosa* were slightly isolated (15.4%) compared to other study from Iran (73.9%) (41). This discrepancy could be in part explained by different definitions for MDR.

There were no significant differences in resistance pattern of *E.coli* and *Klebsiella* spp. Carbapenems and amikacin were the most active

agents against these organisms, a finding that was demonstrated by prior investigators (3,7,41).

In this study, the resistance rate of *E. coli* to ciprofloxacin (47.5%) was similar to another study in Iran (40.2%)(42), however, the resistance rate of *E. coli* and *Klebsiella* to ampicillin, cefixime, and trimethoprim-sulfamethoxazole were high. This is in agreement with other studies (3,7,23). These drugs have been commonly overused in outpatients for many years, hence, high resistance rate is expected.

Prior investigators have proposed high resistance of *S. aureus* to penicillin (7,23), for example, in USA, the incidence of resistance of *S. aureus* from blood cultures to penicillin was 90% (3). Our results revealed more or less the same resistance rate (95%).

Antimicrobial resistance to erythromycin, gentamicin, ciprofloxacin, meropenem were above 30%, but none of the strains showed resistance to vancomycin, therefore, vancomycin could be safely used in multidrug resistant strains. Similar results have been reported by other researchers (7,23,43).

Although high rates of antimicrobial resistance were observed in this study, there were several encouraging observations regarding specific antimicrobial agents. Firstly, we did not observe any vancomycin-resistant or –intermediate strains among isolates of *S. aureus*. Secondly, rifampin had a good activity against most of gram-positive organisms so could help us in the treatment of severe and life threatening gram-positive infections. Thirdly, ciprofloxacin had a good activity against most of gram-negative organisms, and finally, carbapenems (imipenem and meropenem) were strongly active against strains of Enterobacteriaceae (*E. coli*, *Klebsiella*) that were resistant to third generation of cephalosporines.

In conclusion, our data demonstrate an unusual range of organisms causing bloodstream infections, which differs significantly from previously published data. Of particular interest is the high rate of *Acinetobacter* spp. These results highlight

the important role of local microbiology laboratories to address appropriate empiric antibiotic therapy. Prompt, effective therapy requires up to date knowledge of locally prevalent organisms, and ongoing surveillance for emerging antibiotic resistance. The rise in antibiotic resistance in blood isolates emphasizes the importance of hospital infection control, rational prescribing policies, and need for new antimicrobial drugs and vaccines. Our results seem helpful in providing useful guidelines for choosing an effective antibiotic in cases of septicemia and salvage therapy against hospital resistant strains. Lastly, we emphasize that empiric therapy should be guided by local susceptibility data when available, however, in the absence of such information, surveillance data can help with therapeutic choices.

Our results should be interpreted cautiously since this study included a single referral hospital with few numbers of bacteremia, as well as a short study period.

ACKNOWLEDGEMENT

This research was funded by Iran University of Medical Science. We thank Drs. R. Setareh Shenasi and N. Askari (Department of Microbiology, Rasul Akram Hospital) for their kind cooperation.

REFERENCES

1. Diekma DJ, Beekman SE, Chapin KC, Morel KA, Munson E, Doern GV. Epidemiology and outcome of nosocomial and community onset bloodstream infection. *J Clin Microbiol* 2003;41:3655-60.
2. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. *Clin Infect Dis* 1997;24:584-602.
3. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENETRY

94 Antimicrobial resistance of blood culture isolates

- antimicrobial surveillance program (United states and Canada, 1997). *Antimicrob Agents Chemother* 1998; 42(7):1762-70.
4. Munson EL, Diekema DJ, Beekmann SE, Chapin KC, Doern GV. Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management. *J Clin Microbiol* 2003;41(1):495-97.
 5. Laupland KB, Davis HD, Church DL, Louie TJ, Dool JS, Zygun DA, et al. Bloodstream infection-associated sepsis and septic shock in critically ill adults: a population-based study. *Infection* 2004;2:59-64.
 6. Uslan DZ, Crane SJ, Steckelberg JM, Cockerill FR, Sauver JL, Wilson WR, et al. Age- and sex-associated trends in bloodstream infection. *Arch Intern Med* 2007; 167:834-39.
 7. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001. *Braz J Infec Dis* 2004;8(1):25-79.
 8. Valles J, Rello J, Ochagavia A, Garnacho J, Alcalá MA. Community-acquired bloodstream infection in critically ill adult patients. *Chest* 2003; 123:1615-24.
 9. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENENTRY antimicrobial surveillance program (1997-2002). *Diagn Microbiol Infect Dis* 2004;50:59-69.
 10. Sligl W, Taylor G, Brindley PG. Five years of nosocomial gram-negative bacteria in a general intensive care unit: epidemiology, antimicrobial susceptibility patterns, and outcomes. *Int J Infect Dis* 2006;10:320-25.
 11. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. *Clin Infect Dis* 2005;41(4):848-54.
 12. Hadadi A, Rasoulinejad M, Maleki Z, Yonesian M, Shirani A, Kourorian Z. Antimicrobial resistance pattern of gram-negative bacilli of nosocomial origin at 2 university hospital in Iran. *Diagn Microbiol Infect Dis* 2008;60:301-5.
 13. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. *Crit Care Med* 2006;34(2):344-53.
 14. Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systemic surveillance cultures in an adult intensive care unit. *Crit Care Med* 2006;34:653-59.
 15. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definition conference. *Intensive Care Med* 2003;29:530-8.
 16. Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenber P, Woods G, editors. *Koneman's color atlas and textbook of diagnostic microbiology*. 6th ed. Philadelphia: Lippincott Williams & Wilkins. 2006;p: 100-2.
 17. NCCLS 2003. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8. Wayne, PA, NCCLS.
 18. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing; thirteen informational supplement. Document M100-S13. Wayne, PA, 2003.
 19. Bekeris LG, Tworek JA, Walsh MK, Valenstein PN. Trends in blood culture contamination. *Arch Pathol Lab Med* 2005;129:1222-25.
 20. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* from hospitalized patients in the United States, 1998 to 2001. *Antimicrob Agents Chemother* 2003; 47(25):1681-88.
 21. Douglas MW, Lum G, Roy J, Fisher DA, Anstey NM, Currie BJ. Epidemiology of community-acquired and nosocomial bloodstream infections in tropical Australia: a 12-month prospective study. *Trop Med Int Health* 2004; 9(7):795-804.
 22. Sucu N, Caylan R, Aydin K, Yilmaz G, Aktöz B, Koksall I. Prospective evaluation of blood cultures in medical faculty hospital of Blacksea Technical University. *Mikrobiyoloji Bulteni* 2005;39:455-64.
 23. Garg A, Anupurba S, Garg J, Goyal RK, Sen MR. Bacteriological profile and antimicrobial resistance of blood culture isolates from a university hospital. *JACM* 2007; 8(2):139-43.
 24. Munoz-Price L, Weinstein RA. *Acinetobacter* infection. *N Eng J Med* 2008;358:1271-81.
 25. Tien HC, Batted A, Bryce EA, Fuller J, Mulvey M, Bernard K, et al. Multi-drug resistant *acinetobacter* infections in critically injured Canadian forces soldiers. *BMC Infect Dis* 2007;7:95.
 26. Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, et al. Epidemiology of severe sepsis in critically ill surgical

- patients in ten university hospitals in China. *Crit Care Med* 2007;35:2538-46
27. Houang ET, Chu YW, Lenung CM, Chu KY, Berlau J, NG KC, et al. Epidemiology and infection control implications of *Acinetobacter* spp. in Hong Kong. *J Clin Microbiol*.2001;39(1):228-34.
28. Segal SC, Zaoutis TE, Kagen J, Shah SS. Epidemiology of and risk factors for acinetobacter species blood stream infection in children. *Pediatr Infect Dis* 2007;26(10):920-6.
29. Ranjbar R, Sadeghifard N, Ahmadi A, Izadi M, Zaeimi-Yazdi J, Ghasemi A, et al. Antimicrobial susceptibility and AP-PCR typing of acinetobacter spp. strains. *Iranian Journal of Public Health* 2007;36(4):50-56.
30. McGowan JE. Resistance in non-fermenting gram-negative bacteria: multidrug resistance to the maximum. *Am J Med* 2006;119(6A):529-36.
31. Albrecht MA, Griffith ME, Murray CK, Chung KK, Horvath EE, Ward JA, et al. Impact of acinetobacter infection on the mortality of burn patients. *J Am Coll Surg* 2006;203:546-50.
32. Ling TK, Ying CM, Lee CC, Liu ZK. Comparison of antimicrobial resistance of acinetobacter baumannii clinical isolates from Shanghai and Hong Kong. *Med Princ Pract* 2005;14(5):338-41.
33. Echeverria MJ, Lopez de Goicoechea MJ, Avarza R, Vecino Y, Lazpita MA, Ibarretxebea AB, et al. In vitro activity of 9 antibiotics and 3 beta-lactamase inhibitors against 107 clinical isolate of acinetobacter baumannii. *Enferm Infec Microbiol Clin* 1997; 15(6):319-22.
34. Shi ZY, Liu PY, Lau Y, Liu Y, Hu BS, Shir J-M. Antimicrobial susceptibility of clinical isolates of acinetobacter baumannii. *Diagn Microbiol Infect Dis* 1996;24(2):81-5.
35. Livermore DM. Multiple mechanisms of antimicrobial resistance in *Pseudomonas aeruginosa*: our worst nightmare? *Clin Infect Dis* 2002;34:634-40.
36. Heinemann B, Wisplinghoff H, Edmond M, Seifert H. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined acinetobacter baumannii strains. *Antimicrob Agents Chemother* 2000;44(8): 2211-13.
37. Villers D, Espaze E, Coste-Burel M, Giauffret F, Ninin E, Nicolas F, et al. Nosocomial *Acinetobacter baumannii* infections: microbiological and clinical epidemiology. *Ann Intern Med* 1998;129(3):182-9.
38. Karimi Shahidi M, Dabag Mohammadi AG, Mohajer Iravani B, Meigoni MA. The epidemiology and susceptibility study of inpatient blood cultures in Amir Alam Hospital 1998-2000. *Journal of Tehran University of Medical Sciences* 2002;6(1):31-37. (Abstract)
39. Moniri R, Mosayebi Z, Movahedian AH, Mossavi GhA. Increasing trend of antimicrobial drug-resistance in *pseudomonas aeruginosa* causing septicemia. *Iranian Journal of Public Health* 2006;35(1):58-62.
40. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among acinetobacter calcoaceticus-baumannii complex and enterobacteriaceae collected as part of the tigecycline evaluation and surveillance trial. *J Infect* 2007;55(1):49-57.
41. Jones NR, Sader HS, Fritsche TR, Pottumarthy S. Comparison of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENENTRY antimicrobial surveillance program (1998-2004). *Diagn Microbiol Infect Dis* 2007;57:109-16.
42. Nakhjavani FA, Mirsalehian A, Hamidian M, Kazemi A, Mirafshar M, Jabalameli F. Antimicrobial susceptibility testing for *E.coli* strains to fluoroquinolones, in urinary tract infections. *Iranian Journal of Public Health* 2007;36(1):89-92.
43. Poiata A, Tuchilus C, Ambarus A, Teodor A, Teodorescu I, Luca V, et al. Antimicrobial susceptibility of *Staphylococcus aureus* isolated from colonized hospital personnel. *Rev Med Chir Soc Med Nat Iasi* 2006;110(3):723-6.